Kennedy Capital Management LLC Grows Position in NewAmsterdam Pharma Company N.V. $NAMS

Kennedy Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 17.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 172,931 shares of the company’s stock after buying an additional 26,216 shares during the period. Kennedy Capital Management LLC owned approximately 0.15% of NewAmsterdam Pharma worth $6,066,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC boosted its position in shares of NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Navalign LLC purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $46,000. Empowered Funds LLC purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $85,000. Finally, NBC Securities Inc. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $86,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $30.60 on Tuesday. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -17.09 and a beta of 0.07. The stock’s 50-day simple moving average is $33.39 and its two-hundred day simple moving average is $33.58. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.63 and a 52-week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $869,158.57. This trade represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 12.74% of the company’s stock.

Analyst Ratings Changes

NAMS has been the topic of several recent analyst reports. Guggenheim increased their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Truist Financial initiated coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Finally, Needham & Company LLC raised their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $48.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.